Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 207,014,144
  • Shares Outstanding, K 2,294,294
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.59
  • Price/Sales 3.94
  • Price/Cash Flow 10.94
  • Price/Book 4.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.20
  • Number of Estimates 3
  • High Estimate 1.21
  • Low Estimate 1.18
  • Prior Year 1.26
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.03 +7.08%
on 07/12/19
95.00 -0.78%
on 07/18/19
+2.96 (+3.24%)
since 06/18/19
3-Month
74.97 +25.73%
on 04/22/19
95.00 -0.78%
on 07/18/19
+17.85 (+23.36%)
since 04/18/19
52-Week
70.94 +32.88%
on 07/19/18
95.00 -0.78%
on 07/18/19
+23.05 (+32.36%)
since 07/18/18

Most Recent Stories

More News
Netflix, United Rentals fall while Union Pacific, eBay rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:

ASH : 75.50 (-2.79%)
UNP : 174.25 (+5.89%)
NVS : 94.26 (+4.47%)
URI : 121.11 (-7.89%)
PM : 87.71 (+8.22%)
Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.

MRK : 82.69 (+0.94%)
AGN : 162.05 (-0.25%)
NVS : 94.26 (+4.47%)
GSK : 41.41 (+0.66%)
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

MRK : 82.69 (+0.94%)
NVS : 94.26 (+4.47%)
ABBV : 68.25 (-0.10%)
RHHBY : 34.4700 (+0.88%)
Novartis: 2Q Earnings Snapshot

BASEL, Switzerland (AP) _ Novartis AG (NVS) on Thursday reported second-quarter earnings of $6.8 billion.

NVS : 94.26 (+4.47%)
LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the Food & Drug Administration (FDA) granted rare pediatric...

IPXL : 18.30 (unch)
NVS : 94.26 (+4.47%)
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

Novartis International AG / Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased . Processed...

NVS : 94.26 (+4.47%)
Epilepsy Therapeutic Market SWOT Analysis | Key Players- Abbott, GlaxoSmithKline, UCB, Cephalon, Johnson & Johnson, Pfizer, Novartis

A new research study from HTF MI with title provides an in-depth assessment of the Epilepsy Therapeutic including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies,...

VRX.TO : 30.80 (-3.33%)
ABT : 87.76 (+2.33%)
NVS : 94.26 (+4.47%)
GSK : 41.41 (+0.66%)
Why Earnings Season Could Be Great for Novartis (NVS)

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NVS : 94.26 (+4.47%)
Myasthenia Gravis Treatment Market to see strong growth and various Market opportunities during forecasts period...

VRX.TO : 30.80 (-3.33%)
NVS : 94.26 (+4.47%)
ABBV : 68.25 (-0.10%)
TEVA : 7.83 (-3.45%)
GSK : 41.41 (+0.66%)
BMY : 44.05 (-0.18%)
Trade Talk Cools Off Record-Setting Market

Trade Talk Cools Off Record-Setting Market

NFLX : 325.21 (-10.27%)
YNDX : 39.61 (+0.10%)
WWE : 70.20 (-2.61%)
YETI : 32.20 (+0.53%)
NVS : 94.26 (+4.47%)
VSLR : 8.34 (+0.36%)
GDI : 32.78 (-0.46%)
OGI : 6.43 (-6.13%)
WDC : 52.88 (+2.70%)
SPLK : 138.39 (-0.12%)
ZBRA : 182.69 (-7.67%)
TRHC : 55.14 (+0.77%)
SPWR : 10.91 (-1.18%)
PANW : 222.31 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 95.85
1st Resistance Point 95.06
Last Price 94.26
1st Support Level 93.41
2nd Support Level 92.55

See More

52-Week High 95.00
Last Price 94.26
Fibonacci 61.8% 85.81
Fibonacci 50% 82.97
Fibonacci 38.2% 80.13
52-Week Low 70.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar